Amanda Winters, MD, PhD
Assistant Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation

Photo
Download CV
Medical School:
  • MD, Tulane University School of Medicine (2011)
Graduate School :
  • PhD, Tulane University School of Medicine (2011)
Undergraduate School:
  • BS, University of Southern Mississippi (MS) (2004)
Internship:
  • Cincinnati Children's Hospital Medical Center Program (2012)
Residency:
  • Cincinnati Children's Hospital Medical Center Program, Pediatrics (2014)
Fellowships:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (2017)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation

Professional Titles

  • Assistant Professor, Pediatric Hematology/Oncology/BMT
  • Associate Program Director of Pediatric Hematology/Oncology Fellowship

Research Interests

I perform in-laboratory testing of new drugs that have been developed for acute myeloid leukemia (AML). These drugs are being tested in clinical trials in adults, and may be useful for children with AML as well. I'm also trying to develop more sensitive methods to detect molecular disease when it is not otherwise detectable after therapy, so we can more accurately know how much therapy is needed for individual patients.

Teaching

  • Assistant Professor (2019)
    School of Medicine, Pediatrics

Publications

  • Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax? ?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 Jun;62(6):1466-1473. PubMed PMID: 33375853
  • Cherry E, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky JT, Inguva A, Minhajuddin M, Pei S, Stevens BM, Winters AC, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood Adv. 2021 Oct 5. [Epub ahead of print] PubMed PMID: 34610123
  • Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D'Alessandro A, Jordan CT. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020 Aug 14. [Epub ahead of print] PubMed PMID: 32822582
  • Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer. 2020 Jul 31;:e28398. [Epub ahead of print] PubMed PMID: 32735397
  • Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 Apr;10(4):536-551. PubMed PMID: 31974170
  • Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leuk Res. 2019 Jun;81:43-49. PubMed PMID: 31009835
  • Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019 Jun;74:52-63.e3. PubMed PMID: 31136781
  • Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018 Dec;24(12):1859-1866. PubMed PMID: 30420752
  • Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D’Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, Jordan CT. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nature Cancer (2020) [accepted].
  • Amaya M, Inguva A, …, Winters A, …, Jordan C. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood (2021) [accepted].
  • Gutman J, Pollyea D, …, Winters A, …, Abbott D. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplantation (2021) [accepted].
View All (11 Total) View Less

Professional Memberships

  • American Board of Pediatrics, Board-Certified, General Pediatrics
  • American Academy of Pediatrics, Member
  • American Society of Pediatric Hematology/Oncology, Member
  • American Society of Hematology, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado
Center Affiliations

Specialty Information

Specialties
  • Pediatric Hematology / Oncology, Board Certification (2019)
  • American Board of Pediatrics, Pediatric Hematology/Oncology, Board Certification (2019)
  • American Board of Pediatrics, General Pediatrics, Board Certification (2014)
Conditions & Treatments
  • Cancers
  • Cancers - Aplastic Anemia
  • Cancers - Chemotherapy
  • Cancers - Leukemia (Childhood)
  • Cancers - Myelodysplastic Syndrome
  • Cancers - Lymphoma
  • Cancers - Pediatric Cancer
Clinical Interests
My clinical focus is in the treatment of children with cancer, in particular leukemias and conditions that may lead to leukemias such as inherited bone marrow failure syndromes or myelodysplastic syndromes (MDS).

Care Philosophy
I believe in providing the most evidence-based and compassionate care possible to my patients and their families. A diagnosis of cancer is one of the worst experiences of a family's life, and making it easier or more manageable to the child and his/her family in some small way is as important to me as providing physical healing. I and my colleagues also strive to treat patients with the most up-to-date in cancer therapies available.

Personal Interests
In addition to clinical care of patients, which is most important to me, I am interested in research that brings newer and better drugs into the care of children with cancer. I am also passionate about medical education.

General Information

Medical Schools:
  • MD, Tulane University School of Medicine (2011)
Graduate Schools:
  • PhD, Tulane University School of Medicine (2011)
Undergraduate Schools:
  • BS, University of Southern Mississippi (MS) (2004)
Internships:
  • Cincinnati Children's Hospital Medical Center Program (2012)
Residency Programs:
  • Cincinnati Children's Hospital Medical Center Program, Pediatrics (2014)
Fellowships:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (2017)
Download CV
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;